American Capital Advisory’s Biogen BIIB Stock Holding History

American Capital Advisory’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.25K	Buy	15 +4	+36%	+$765	﹤0.01%	526
2026 Q1	$2.03K	Buy	11 +3	+38%	+$553	﹤0.01%	538
2025 Q4	$1.42K	Hold	8	–	–	﹤0.01%	524
2025 Q3	$1.13K	Hold	8	–	–	﹤0.01%	518
2025 Q2	$1.01K	Buy	8 +6	+300%	+$748	﹤0.01%	494
2025 Q1	$282	Buy	+2	New	+$286	﹤0.01%	637
2024 Q4	–	Hold	0	–	–	–	468
2024 Q3	–	Hold	0	–	–	–	475
2024 Q2	–	Hold	0	–	–	–	432
2024 Q1	–	Hold	0	–	–	–	453
2023 Q4	–	Hold	0	–	–	–	432

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

American Capital Advisory's BIIB Position: Q2 2026 in Review

American Capital Advisory increased its Biogen (BIIB) stake by 36% in Q2 2026, buying an estimated $765 and bringing the position to 15 shares worth $3.25K. The position accounts for ﹤0.01% of the portfolio, ranked #526.

American Capital Advisory first reported a position in BIIB in Q1 2025 and has held it in 6 quarters since. 569 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

American Capital Advisory held 15 shares of Biogen worth $3.25K as of Q2 2026.
American Capital Advisory bought 4 Biogen shares in Q2 2026, an estimated $765.
Biogen made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #526 holding.
American Capital Advisory first reported a position in Biogen in Q1 2025 and has held it in 6 quarters since.
569 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.